CT0590 is a triple-knockout allogeneic BCMA CAR T-cell therapy designed to overcome host-versus-graft immune reactions, armed with an NKG2A CAR to resist NK cell-mediated killing.
Preclinical studies demonstrated enhanced resistance against host NK cells and robust anti-myeloma activity in vivo.
In a phase 1 first-in-human study involving 5 heavily pretreated patients with relapsed/refractory multiple myeloma and plasma cell leukemia, CT0590 showed a favorable safety profile without graft-versus-host disease (GVHD) or dose-limiting toxicities.
Clinical responses included stringent complete responses with durable remissions beyond 20 months, associated with high universal CAR T-cell expansion and elevated baseline NKG2A expression on NK cells in responders.
